UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 94

Sortiert nach

Polycomb Repressive Complex 2 Regulates Normal Hematopoietic Stem Cell Function in a Developmental-Stage-Specific Manner

Cell stem cell, 2014-01, Vol.14 (1), p.68-80

2014

Volltextzugriff (PDF)

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Cell chemical biology, 2020-01, Vol.27 (1), p.41-46.e17

2020

Volltextzugriff (PDF)

Modeling initiation of Ewing sarcoma in human neural crest cells

PloS one, 2011-04, Vol.6 (4), p.e19305-e19305

2011

Volltextzugriff (PDF)

Outcome-Driven Cluster Analysis with Application to Microarray Data

PloS one, 2015-11, Vol.10 (11), p.e0141874-e0141874

2015

Volltextzugriff (PDF)

Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase

Journal of medicinal chemistry, 2021-12, Vol.64 (23), p.17146-17183

2021

Volltextzugriff (PDF)

Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase

Bioorganic & medicinal chemistry letters, 2021-05, Vol.39, p.127904-127904, Article 127904

2021

Volltextzugriff (PDF)

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600 -mutated Metastatic Melanoma

Clinical cancer research, 2019-06, Vol.25 (11), p.3239-3246

2019

Volltextzugriff (PDF)

Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

PloS one, 2015-10, Vol.10 (10), p.e0139679

2015

Volltextzugriff (PDF)

Informatively clustering longitudinal microarrays using binary or survival outcome data

Communication in statistics. Case studies and data analysis, 2018-01, Vol.4 (1), p.18-27

2018

Volltextzugriff (PDF)

Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches

Journal of medicinal chemistry, 2024-05, Vol.67 (11), p.8962-8987

2024

Volltextzugriff (PDF)

Diverse Drug Combinations with an Eed Inhibitor Confer Context-Specific Benefit across Multiple Tumor Types

Blood, 2021-11, Vol.138 (Supplement 1), p.2274-2274

2021

Volltextzugriff (PDF)

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5225-5235

2021

Volltextzugriff (PDF)

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5225-5235

2021

Volltextzugriff (PDF)

Varied Clinical Ketogenic Diets Elicit Both Shared and Unique Functional and Taxonomic Responses on the Human Gut Microbiome in Refractory Epilepsy

Current developments in nutrition, 2022-06, Vol.6 (Supplement_1), p.1024-1024

2022

Volltextzugriff (PDF)

Extended 5-Year Follow-Up Results of a Phase 1b Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Clinical cancer research, 2019-11, Vol.26 (1), p.46-53

2019

Volltextzugriff (PDF)

Dietary Fibers in Clinical Ketogenic Diets Promotes Seizure Resistance in Mice Through Modulation of Gut Microbiome

Current developments in nutrition, 2024-07, Vol.8, p.103439, Article 103439

2024

Volltextzugriff (PDF)

COLET (NCT02322814): A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS1100-TPS1100

2016

Volltextzugriff (PDF)

Abstract PR03: Prmt1 and Prmt1-dependent translation initiation are critical vulnerabilities of osteosarcoma

Cancer research (Chicago, Ill.), 2016-03, Vol.76 (5_Supplement), p.PR03-PR03

2016

Volltextzugriff (PDF)

Abstract LB-A09: EED targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.LB-A09-LB-A09

2019

Volltextzugriff (PDF)

Genomic features of exceptional response in vemurafenib ± cobimetinib–treated patients with BRAFV600-mutated metastatic melanoma

Clinical cancer research, 2019-03, Vol.25 (11), p.3239-3246

2019

Volltextzugriff (PDF)

Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF -mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9530-9530

2016

Volltextzugriff (PDF)

Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9533-9533

2016

Volltextzugriff (PDF)

Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF V600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9522-9522

2018

Volltextzugriff (PDF)

Polycomb repressive complex 2 regulates hematopoietic stem cell maintenance and differentiation in a developmental stage-specific manner

Cell stem cell, 2013-11, Vol.14 (1), p.68-80

2013

Volltextzugriff (PDF)

Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF -mutant melanoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.9020-9020

2015

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(88)

Publikationsform

Sprache

Englisch
(94)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Polycomb Repressive Complex 2 Regulates Normal Hematopoietic Stem Cell Function in a Developmental-Stage-Specific Manner

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Modeling initiation of Ewing sarcoma in human neural crest cells

Outcome-Driven Cluster Analysis with Application to Microarray Data

Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase

Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600 -mutated Metastatic Melanoma

Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

Informatively clustering longitudinal microarrays using binary or survival outcome data

Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches

Diverse Drug Combinations with an Eed Inhibitor Confer Context-Specific Benefit across Multiple Tumor Types

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Varied Clinical Ketogenic Diets Elicit Both Shared and Unique Functional and Taxonomic Responses on the Human Gut Microbiome in Refractory Epilepsy

Extended 5-Year Follow-Up Results of a Phase 1b Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Dietary Fibers in Clinical Ketogenic Diets Promotes Seizure Resistance in Mice Through Modulation of Gut Microbiome

COLET (NCT02322814): A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC)

Abstract PR03: Prmt1 and Prmt1-dependent translation initiation are critical vulnerabilities of osteosarcoma

Abstract LB-A09: EED targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex

Genomic features of exceptional response in vemurafenib ± cobimetinib–treated patients with BRAFV600-mutated metastatic melanoma

Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF -mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study

Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study

Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF V600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study

Polycomb repressive complex 2 regulates hematopoietic stem cell maintenance and differentiation in a developmental stage-specific manner

Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF -mutant melanoma

Aktive Filter

Suchergebnisse filtern